Rolimus (Everolimus) is a drug belonging to the group of proliferative signal inhibitors (mTOR inhibitors). It is an immunosuppressant and suppresses the activation of the T-cell link of the immune system. On the surface of T-lymphocytes there are specific receptors for the so-called growth factors – interleukins. The binding of interleukins to their receptors, mediated by the presence of a foreign antigen in the body, triggers a chain of molecular interactions inside T cells, called the intracellular signaling pathway, which normally leads to the proliferation (i.e. multiplication) of T lymphocytes. Everolimus blocks one of the stages of intracellular signal transmission by interacting with the mTOR molecule, which leads to the arrest of cell division.
EVERTOR (Everolimus) is used to prevent rejection of transplanted organs after heart and kidney transplantation, as well as to treat certain cancers (kidney cancer).